This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reyes, N. Articles by Hegde, S. S. Search for Related Content PubMed PubMed Citation Articles by Reyes, N. Articles by Hegde, S. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2005, p. 4344-4346, Vol. 49, No. 10
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.10.4344-4346.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus

Noe Reyes, Robert Skinner, Koné Kaniga, Kevin M. Krause, Josephine Shelton, Glenmar P. Obedencio, Alexander Gough, Michael Conner, and Sharath S. Hegde^*

Theravance, Inc., 901 Gateway Blvd., South San Francisco, California 94080

Received 17 March 2005/ Returned for modification 15 May 2005/ Accepted 6 July 2005

The efficacy of telavancin, a bactericidal lipoglycopeptide, was compared to that of vancomycin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) in a murine pneumonia model. Telavancin produced greater reductions in lung bacterial titer and mortality than did vancomycin and linezolid at human doses equivalent to those described by the area under the concentration-time curve. These results suggest the potential utility of telavancin for treatment of MRSA pneumonia.

Present address: Peninsula Pharmaceuticals, Inc., 1900 Charleston Rd., Mountain View, Ca 94043.

This article has been cited by other articles:

• Gotfried, M. H., Shaw, J.-P., Benton, B. M., Krause, K. M., Goldberg, M. R., Kitt, M. M., Barriere, S. L. (2008). Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics. Antimicrob. Agents Chemother. 52: 92-97 [Abstract] [Full Text]  
• Hegde, S. S., Reyes, N., Skinner, R., Difuntorum, S. (2008). Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 61: 169-172 [Abstract] [Full Text]  
• Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
• Odenholt, I., Lowdin, E., Cars, O. (2007). Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 51: 3311-3316 [Abstract] [Full Text]  
• Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  
• Barcia-Macay, M., Lemaire, S., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F. (2006). Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 1177-1184 [Abstract] [Full Text]  
• Reyes, N., Skinner, R., Benton, B. M., Krause, K. M., Shelton, J., Obedencio, G. P., Hegde, S. S. (2006). Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 462-465 [Abstract] [Full Text]